Ask AI
ProCE Banner Activity

Just in Time: Considering Dopamine Receptor-Targeted Therapy in PD

Clinical Thought

The introduction of selective D1/D5 receptor targeting represents a novel treatment option for patients with Parkinson's disease. This ClinicalThought reviews the roles of dopamine receptors in motor function, limitations of traditional dopamine agonists, and evidence for newer therapeutic approaches, examining how receptor selectivity, drug delivery, and tolerability may influence clinical practice.

Released: November 02, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an independent educational grant from AbbVie.

AbbVie

Target Audience

This activity is intended for healthcare professionals who care for patients with PD, including movement disorder specialists, neurologists, and advanced practice providers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the major dopamine receptor families and how their location and signaling roles influence PD pathophysiology

  • Compare the mechanisms, efficacy, safety, and delivery of dopamine-targeted therapies used in PD

  • Apply data from clinical trials of dopamine-targeted therapies to inform individualized treatment sequencing decisions for patients with early and advanced PD

Financial Disclosures

Primary Author

Daniel Kremens, MD, JD: consultant/advisor/speaker: AbbVie, Acadia, Amneal, BlueRock, Lundbeck, Merz, Neurocrine, Supernus, Teva.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.